Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, June 9, 2010
Tue, June 8, 2010 CPF, HAFC, IMUC, XRM, GCTAY, AXMP Have Been Added To Naked Short Lists Today
June 8, 2010 /M2 PRESSWIRE/ BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold lists. Central Pacific Financial (NYSE: CPF), Hanmi Financial Corp (NASDAQ: HAFC), ImmunoCellular Therapeutics (OTCBB: IMUC), Xerium Technologies (NYSE: XRM), Gamesa Corp (OTC: GCTAY) and AXM Pharma (OTC: AXMP). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Central Pacific Financial Corp. (NYSE: CPF) operates as the bank holding company for Central Pacific Bank that provides commercial banking services to businesses, professionals, and individuals in Hawaii. The company offers various deposit products and services, including time and demand deposits, personal and business checking accounts, savings accounts, money market accounts, and time certificates of deposit. Its loan portfolio comprises commercial loans, construction loans, commercial and residential mortgage loans, consumer loans, and commercial real estate loans. The company also provides various products and services consisting of debit cards, Internet banking, cash management services, travelera�s checks, safe deposit boxes, international banking services, night depository facilities, and wire transfers. In addition, it offers wealth management products and services, including non-deposit investment products, annuities, insurance, investment management, asset custody, and general consultation and planning services. As of March 16, 2010, it operated 37 branches and approximately 100 automated teller machines in Hawaii. The company was founded in 1954 and is based in Honolulu, Hawaii. There is a failure to deliver in shares of CPF.
Hanmi Financial Corporation (NASDAQ: HAFC) operates as the holding company for Hanmi Bank that provides general business banking products and services in the United States. Its deposit product line comprises business and personal checking accounts, savings accounts, negotiable order of withdrawal accounts, money market accounts, and certificates of deposit. The companya�s loan portfolio includes real estate loans, such as commercial property, construction, and residential property loans; commercial and industrial loans comprising commercial term loans, commercial lines of credit, small business administration loans, and international trade finance; and consumer loans consisting of automobile loans, secured and unsecured personal loans, home improvement loans, home equity lines of credit, overdraft protection loans, and unsecured lines of credit and credit cards. It also offers various insurance products, such as life, commercial, automobile, health, and property and casualty. The company serves the Korean-American community, as well as other communities in the multi-ethnic populations of Los Angeles County, Orange County, San Bernardino County, San Diego County, the San Francisco Bay area, and the Silicon Valley area in Santa Clara County. As of December 31, 2009, it operated a branch network of 27 full-service branch offices in California; and 2 loan production offices in Virginia and Washington. The company was founded in 1981 and is headquartered in Los Angeles, California. There is a failure to deliver in shares of HAFC.
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a development stage company, focuses on developing and commercializing therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens; peptide based immunotherapies targeting cancer stem cells; and monoclonal antibodies to diagnose and treat various cancers. The company is developing dendritic cell based vaccine product candidate that has completed phase 1 of clinical trial to treat glioblastoma multiforme, a type of brain tumor. It is also developing peptide based off-the-shelf vaccine to target glioblastoma multiforme and multiple cancer indications; and various monoclonal antibody product candidates targeting small cell lung cancer, pancreatic cancer, multiple myeloma, and ovarian cancer. ImmunoCellular Therapeutics, Ltd. has an option license agreement with Roche Group to acquire a license to develop and commercialize ICT-69, its monoclonal antibody product candidate targeting multiple myeloma and ovarian cancer. The company is based in Woodland Hills, California. There is a failure to deliver in shares of IMUC.
Xerium Technologies, Inc. (NYSE: XRM) engages in the manufacture and supply of consumable products that are used in the production of paper primarily in North America, Europe, South America, and the Asia-Pacific. It operates in two segments: Clothing and Roll Covers. The Clothing segment manufactures clothing products, such as forming fabrics, press felts, and dryer fabrics that are used on paper-making machines. This segment also manufactures clothing, which is used in other industrial applications, such as steel, plastics, leather, and textiles manufacturing; and auto-joining equipment used on paper-making machines. The Roll Covers segment manufactures, refurbishes, and replaces covers for working rolls, including vacuum rolls and press rolls; calendar rolls; and coater rolls that are used on paper-making machines. This segment also provides roll cover refurbishment services for previously installed roll covers; and mechanical services for the internal mechanisms of rolls. In addition, it manufactures and repairs spreader rolls. Xerium Technologies markets its products under the Huyck Wangner, Weavexx, Stowe Woodward, Mount Hope, Robec, and Xibe brand names. The company was founded in 1999 and is based in Raleigh, North Carolina. There is a failure to deliver in shares of XRM.
Gamesa Corporacion Tecnologica, S.A. (OTC: GCTAY) engages in design, manufacture, distribution, and installation of sustainable energy solutions. The company engages in the manufacture of wind turbines generators and wind power components; and development, promotion and sale of wind farms. It also manufactures blades, root joints, blade moulds, gearboxes, generators, converters, and towers, as well as assembles wind turbines. The company has operations primarily in Europe, the United States, and China. The company was formerly known as Grupo Auxiliar Metalurgico, S.A. and changed its name to Gamesa Corporacion Tecnologica, S.A. in June 2002. Gamesa Corporacion Tecnologica, S.A. was founded in 1976 and is headquartered in Vitoria-Gasteiz, Spain. There is a failure to deliver in shares of GCTAY.
AXM Pharma, Inc. (OTC: AXMP) engages in the manufacture, marketing, and distribution of over-the-counter and prescription pharmaceutical and neutraceutical products primarily in the Peoplea�s Republic of China. Its products include Asarone, an antiseptic, anti-inflammatory, asthma reducing, and cough prevention tablet; Elegance, a menstrual relief lotion; LiveComf, a compound sulfur cream used to alleviate dermatitis, seborrheica, scabies, acne, and eczema; Bodyward, a tablet to treat allergy caused by penicillin; Reheal, a capsule used to treat reduced memory capacity and impairment of cerebral function caused by acute/chronic cerebrovascular disease, cerebral trauma, and toxic cerebral disease; and LifeGate, an antifatigue capsule used for enhancing energy and vitality. The company also offers a line of vitamin and vitamin supplements. It offers these products through a third party distributor to hospitals and hospital distributors. AXM Pharma also markets its products in Hong Kong, Taiwan, Korea, the Philippines, Indonesia, Malaysia, Singapore, and Thailand. As of December 31, 2005, it held 42 licenses to produce over-the-counter and prescription pharmaceutical products in China. The company was founded in 1999. It was formerly known as Wholesale on the Net, Inc. and changed its name to Wickliffe International Corporation in 2001. Further, the company changed its name to AXM Pharma, Inc. in 2003. AXM Pharma is headquartered in Las Vegas, Nevada. There is a failure to deliver in shares of AXMP.
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,750,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
Contact: Thomas Ronk / CEO www.BUYINS.net (800) 715-9999 tom@buyins.net
- WOPRAI
- support@woprai.com